Complement activation in patients with neuromyelitis optica.

Complement activation in patients with neuromyelitis optica.

Näytä muut versiot (1)

The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a...

Bibliografiset tiedot
Päätekijät:	Nytrova, P, Potlukova, E, Kemlink, D, Woodhall, M, Horakova, D, Waters, P, Havrdova, E, Zivorova, D, Vincent, A, Trendelenburg, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2014

Samankaltaisia teoksia

Complement activation in patients with neuromyelitis optica
Tekijä: Nytrova, P, et al.
Julkaistu: (2014)

C3a complement split product: possible biomarker of disease activity in patients with neuromyelitis optica
Tekijä: Nytrova, P, et al.
Julkaistu: (2013)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
Tekijä: Saadoun, S, et al.
Julkaistu: (2010)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
Tekijä: Waters, P, et al.
Julkaistu: (2016)

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
Tekijä: Jacob, S, et al.
Julkaistu: (2008)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Tekijä: Kitley, J, et al.
Julkaistu: (2012)

Immunological insights into the mechanisms by which RTX is effective in Neuromyelitis Optica spectrum disorders
Tekijä: Damato, V, et al.
Julkaistu: (2019)

Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Tekijä: Woodhall, M, et al.
Julkaistu: (2013)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
Tekijä: Kitley, J, et al.
Julkaistu: (2013)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
Tekijä: Nour, M, et al.
Julkaistu: (2014)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
Tekijä: Absoud, M, et al.
Julkaistu: (2014)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
Tekijä: Tackley, G, et al.
Julkaistu: (2016)

Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica
Tekijä: Kitley, J, et al.
Julkaistu: (2011)

Novel Anti-Neuronal Antibodies in Neuromyelitis Optica Patients with or without Aquaporin-4 Antibodies
Tekijä: Cavus, F, et al.
Julkaistu: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
Tekijä: Kitley, J, et al.
Julkaistu: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
Tekijä: Kitley, J, et al.
Julkaistu: (2013)

Symptomatic brain involvement as the initial manifestation of neuromyelitis optica.
Tekijä: Min, J, et al.
Julkaistu: (2013)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
Tekijä: Kitley, J, et al.
Julkaistu: (2013)

Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4.
Tekijä: Jarius, S, et al.
Julkaistu: (2008)

IgG subclasses of disease-specific antibodies and complement activation in vitro in myasthenia gravis and neuromyelitis optica
Tekijä: Jacob, S, et al.
Julkaistu: (2007)

Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Tekijä: Kim, S, et al.
Julkaistu: (2013)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
Tekijä: Waters, P, et al.
Julkaistu: (2015)

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
Tekijä: Jarius, S, et al.
Julkaistu: (2008)

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
Tekijä: Mader Simone, et al.
Julkaistu: (2011-12-01)

MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY AS A CAUSE OF ACUTE DISSEMINATED ENCEPHALOMYELITIS WITH A NEUROMYELITIS OPTICA-LIKE PHENOTYPE IN ADULTS
Tekijä: Kitley, J, et al.
Julkaistu: (2012)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
Tekijä: Viegas, S, et al.
Julkaistu: (2009)

Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.
Tekijä: Akman-Demir, G, et al.
Julkaistu: (2011)

Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays.
Tekijä: Waters, P, et al.
Julkaistu: (2008)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Tekijä: Collongues, N, et al.
Julkaistu: (2013)

Effect of IgG from seronegative and seropositive neuromyelitis optica patients on mouse brain
Tekijä: Saadoun, S, et al.
Julkaistu: (2013)

Neuromyelitis Optica
Tekijä: Goyal V, et al.
Julkaistu: (2009-10-01)

Neuromyelitis optica
Tekijä: Jacob Anu, et al.
Julkaistu: (2007-01-01)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
Tekijä: Kitley, J, et al.
Julkaistu: (2014)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Tekijä: Kitley, J, et al.
Julkaistu: (2014)

Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis
Tekijä: Petra Nytrova, et al.
Julkaistu: (2022-08-01)

Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
Tekijä: Katsuichi Miyamoto, et al.
Julkaistu: (2023-03-01)

Neuromyelitis optica IgG causes placental inflammation and fetal death.
Tekijä: Saadoun, S, et al.
Julkaistu: (2013)

Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders
Tekijä: Damato, V, et al.
Julkaistu: (2022)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
Tekijä: Sato, D, et al.
Julkaistu: (2014)

Cell-based assay for anti-AQP4 antibody in Korean patients with neuromyelitis optica
Tekijä: Kim, B, et al.
Julkaistu: (2010)